Back to Search
Start Over
Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs.
- Source :
-
Clinical lung cancer [Clin Lung Cancer] 2017 Sep; Vol. 18 (5), pp. e363-e365. Date of Electronic Publication: 2017 Apr 23. - Publication Year :
- 2017
- Subjects :
- Antibodies, Monoclonal therapeutic use
Antineoplastic Agents therapeutic use
Carcinoma, Non-Small-Cell Lung economics
Carcinoma, Squamous Cell economics
Clinical Trials as Topic
Humans
Lung Neoplasms economics
Nivolumab
Prognosis
Antibodies, Monoclonal economics
Antineoplastic Agents economics
Carcinoma, Non-Small-Cell Lung drug therapy
Carcinoma, Squamous Cell drug therapy
Lung Neoplasms drug therapy
Salvage Therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1938-0690
- Volume :
- 18
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Clinical lung cancer
- Publication Type :
- Editorial & Opinion
- Accession number :
- 28502555
- Full Text :
- https://doi.org/10.1016/j.cllc.2017.04.007